Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-213 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARGX-213 | EXPERIMENTAL | Participants receiving the experimental drug |
| Placebo | PLACEBO_COMPARATOR | Participants receiving placebo |
| Name | Type | Description |
|---|---|---|
| ARGX-213 | BIOLOGICAL | Intravenous or subcutaneous administrations of ARGX-213 |
| Placebo | OTHER | Intravenous or subcutaneous administrations of placebo |
Inclusion Criteria: * Is at least the local legal age of consent for clinical studies and is aged 18 to 65 years, inclusive, when signing the ICF * Is a female of nonchild bearing potential (either postmenopausal or surgically sterilized) or a male * Has a body weight between 50 and 100 kg and a BM...
ARGX-213 is an investigational monoclonal antibody being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial assessing its safety in this population. The drug is not approved for any indication and remains under investigation.
ARGX-213 is being developed by argenx SE, a biopharmaceutical company traded on the NASDAQ under the ticker ARGX. The company is conducting clinical trials to evaluate the safety of this investigational monoclonal antibody in healthy volunteers.
ARGX-213 is in Phase 1 clinical development. A Phase 1 trial, NCT06968338, has been completed, evaluating the safety of the drug in healthy volunteers. As an investigational agent, ARGX-213 is not yet approved and is still in early-stage clinical testing.
ARGX-213 has one completed Phase 1 clinical trial, NCT06968338, titled 'A Study to Assess the Safety of ARGX-213 in Healthy Volunteers.' This randomized, double-blind, placebo-controlled study enrolled 88 participants in Canada, with a minimum age of 18 years.
Yes, ARGX-213 is a monoclonal antibody. It is being developed by argenx SE as an investigational therapy. Currently, it is in Phase 1 clinical trials, with a completed study assessing its safety in healthy volunteers.